These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 20041883)

  • 1. The other side of immunoglobulin G: suppressor of inflammation.
    Aschermann S; Lux A; Baerenwaldt A; Biburger M; Nimmerjahn F
    Clin Exp Immunol; 2010 May; 160(2):161-7. PubMed ID: 20041883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous immunoglobulin therapy: how does IgG modulate the immune system?
    Schwab I; Nimmerjahn F
    Nat Rev Immunol; 2013 Mar; 13(3):176-89. PubMed ID: 23411799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 7th International Immunoglobulin Conference: Mechanisms of action.
    Basta M; Branch DR
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):111. PubMed ID: 25546783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sweet SIGNs: IgG glycosylation leads the way in IVIG-mediated resolution of inflammation.
    Brückner C; Lehmann C; Dudziak D; Nimmerjahn F
    Int Immunol; 2017 Dec; 29(11):499-509. PubMed ID: 29300958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-inflammatory actions of intravenous immunoglobulin.
    Nimmerjahn F; Ravetch JV
    Annu Rev Immunol; 2008; 26():513-33. PubMed ID: 18370923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs.
    Anthony RM; Ravetch JV
    J Clin Immunol; 2010 May; 30 Suppl 1():S9-14. PubMed ID: 20480216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of sialic acid as a modulator of the anti-inflammatory activity of IgG.
    Böhm S; Schwab I; Lux A; Nimmerjahn F
    Semin Immunopathol; 2012 May; 34(3):443-53. PubMed ID: 22437760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 7th International Immunoglobulin Conference: Mechanisms of action.
    Basta M; Branch DR
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):87-8. PubMed ID: 25546774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation.
    Kaneko Y; Nimmerjahn F; Ravetch JV
    Science; 2006 Aug; 313(5787):670-3. PubMed ID: 16888140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel roles for the IgG Fc glycan.
    Anthony RM; Wermeling F; Ravetch JV
    Ann N Y Acad Sci; 2012 Apr; 1253():170-80. PubMed ID: 22288459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of differential glycosylation on IgG activity.
    Lux A; Nimmerjahn F
    Adv Exp Med Biol; 2011; 780():113-24. PubMed ID: 21842369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IVIG-mediated effector functions in autoimmune and inflammatory diseases.
    Galeotti C; Kaveri SV; Bayry J
    Int Immunol; 2017 Dec; 29(11):491-498. PubMed ID: 28666326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous immunoglobulins--understanding properties and mechanisms.
    Durandy A; Kaveri SV; Kuijpers TW; Basta M; Miescher S; Ravetch JV; Rieben R
    Clin Exp Immunol; 2009 Dec; 158 Suppl 1(Suppl 1):2-13. PubMed ID: 19883419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective.
    Sibéril S; Elluru S; Graff-Dubois S; Negi VS; Delignat S; Mouthon L; Lacroix-Desmazes S; Kazatchkine MD; Bayry J; Kaveri SV
    Ann N Y Acad Sci; 2007 Sep; 1110():497-506. PubMed ID: 17911465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pro and anti-inflammatory activities of immunoglobulin G.
    Lux A; Aschermann S; Biburger M; Nimmerjahn F
    Ann Rheum Dis; 2010 Jan; 69 Suppl 1():i92-96. PubMed ID: 19995755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc.
    Anthony RM; Nimmerjahn F; Ashline DJ; Reinhold VN; Paulson JC; Ravetch JV
    Science; 2008 Apr; 320(5874):373-6. PubMed ID: 18420934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Use of intravenous polyclonal immunoglobulins in autoimmune and inflammatory disorders].
    Graff-Dubois S; Sibéril S; Elluru S; Negi VS; Delignat S; Mouthon L; Lacroix-Desmazes S; Kazatchkine MD; Bayary J; Kaveri SV
    Transfus Clin Biol; 2007 May; 14(1):63-8. PubMed ID: 17498995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity.
    Quast I; Keller CW; Maurer MA; Giddens JP; Tackenberg B; Wang LX; Münz C; Nimmerjahn F; Dalakas MC; Lünemann JD
    J Clin Invest; 2015 Nov; 125(11):4160-70. PubMed ID: 26436649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. rIgG1 Fc Hexamer Inhibits Antibody-Mediated Autoimmune Disease via Effects on Complement and FcγRs.
    Spirig R; Campbell IK; Koernig S; Chen CG; Lewis BJB; Butcher R; Muir I; Taylor S; Chia J; Leong D; Simmonds J; Scotney P; Schmidt P; Fabri L; Hofmann A; Jordi M; Spycher MO; Cattepoel S; Brasseit J; Panousis C; Rowe T; Branch DR; Baz Morelli A; Käsermann F; Zuercher AW
    J Immunol; 2018 Apr; 200(8):2542-2553. PubMed ID: 29531170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Normal polyspecific immunoglobulin G (IVIg) in the treatment of autoimmune diseases.
    Hurez V; Kaveri SV; Kazatchkine MD
    J Autoimmun; 1993 Dec; 6(6):675-81. PubMed ID: 8155249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.